Clinical Trial

ALL Backbone in AYAs

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * blinatumomab (a type of immunotherapy drug) * cyclophosphamide (a type of chemotherapy drug) * cytarabine (a type of antineoplastic agent) * dexamethasone (a type of synthetic glucocorticoid) * doxorubicin (a type of antineoplastic agent) * etoposide (a type of antineoplastic agent) * mercaptopurine (a type of antineoplastic agent) * methotrexate (a type of chemotherapy drug) * pegaspargase (a type of antineoplastic agent) * vincristine (a type of antineoplastic agent)
Trial Details
NCT Number NCT07227584
Lead Sponsor Dana-Farber Cancer Institute
Conditions Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
Enrollment 67 participants
Start Date 2026-04
Primary Completion 2030-07-31 (estimated)
Study Completion 2035-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-12